NL-OMON46855已完成不适用
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozole - PI3K pathway in pm breast cancer pts treated with everolimus and exemestane
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Adult women (* 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
- •2. Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer.
- •3. Postmenopausal women.
- •4. Disease refractory to non steroidal aromatase inhibitors (NSAI).
排除标准
- •1. HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).
- •2. Previous treatment with mTOR inhibitors.
- •3. Radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within two weeks prior to enrollment. Patients must have recovered from radiotherapy toxicities prior to enrollment.
- •4. Currently receiving hormone replacement therapy, unless discontinued prior to enrollment.
研究者
相似试验
进行中（未招募）
1 期
Analysis of tumor tissue and circulating genetic material in the blood to obtain further insight in the effectiveness of everolimus when combined with exemestane.A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with advanced metastatic breast cancer, who have progressed on anastrozole or letrozole.Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.EUCTR2013-004120-11-NLVU University Medical Center175
招募中
不适用
Onderzoek naar kenmerken in tumorweefsel en bloed, die informatie kunnen geven over de werkzaamheid van everolimus in combinatie met exemestaaborstkanker, mammacarcinoom, gemetastaseerd, everolimus, exemestaan, biomarker.breast cancer, metastatic, everolimus, exemestane, biomarker.NL-OMON21846VU University Medical Center175
已完成
1 期
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid TumorsSolid TumorsNCT02439489Fondazione Michelangelo34
尚未招募
1 期
Based on PI3K/AKT/HIF-1 signaling pathway, to explore the clinical efficacy and mechanism of Zuoguiyin intervention in oxidative stress in the treatment of premature ovarian insufficiencyPremature ovarian insufficiencyITMCTR2023000069Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Unknown
不适用
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerNCT02109913Amsterdam UMC, location VUmc175